The European Commission has granted marketing authorization for Nulibry for injection as the first therapy for the treatment of patients with molybdenum cofactor deficiency
The European Commission (EC) has granted marketing authorization for Nulibry (fosdenopterin) for Injection as the first therapy for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A
The drug is being developed by US biotech BridgeBio Pharma and Sentynl Therapeutics, a USA-based subsidiary of India’s Zydus Lifesciences
MoCD Type A is an ultra-rare and progressive condition known to impact less than 150 patients globally with a median survival of four years.
Nulibry is a first-in-class cPMP substrate replacement therapy that was approved by the FDA in 2021 to reduce the risk of mortality in patients with MoCD Type A. Following this decision by the EC, Nulibry is the first and only approved therapy in the European Union (EU) for MoCD Type A.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins